Compile Data Set for Download or QSAR
Report error Found 30 Enz. Inhib. hit(s) with all data for entry = 50036393 Sort by
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM23408(2-(3,4-dihydroxyphenyl)-3,5,6,7-tetrahydroxy-4H-ch...)
Affinity DataIC50: 100nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM23408(2-(3,4-dihydroxyphenyl)-3,5,6,7-tetrahydroxy-4H-ch...)
Affinity DataIC50: 800nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50009001(CHEMBL8260 | Baicalein | 5,6,7-Trihydroxyflavone |...)
Affinity DataIC50: 1.20E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50033767(CHEMBL170405 | 3,3',4',5',7-pentahydroxy flavone |...)
Affinity DataIC50: 1.60E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM15236(CHEMBL164 | Cannabiscetin | 3,5,7-trihydroxy-2-(3,...)
Affinity DataIC50: 2.50E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50009001(CHEMBL8260 | Baicalein | 5,6,7-Trihydroxyflavone |...)
Affinity DataIC50: 4.30E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50033767(CHEMBL170405 | 3,3',4',5',7-pentahydroxy flavone |...)
Affinity DataIC50: 5.90E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM15236(CHEMBL164 | Cannabiscetin | 3,5,7-trihydroxy-2-(3,...)
Affinity DataIC50: 7.60E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7457(2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromen-4-on...)
Affinity DataIC50: 8.50E+3nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50369073(CHEMBL1159644)
Affinity DataIC50: 1.03E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7460(2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone;...)
Affinity DataIC50: 1.36E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50407724(CHEMBL2029094)
Affinity DataIC50: 2.25E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7460(2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone;...)
Affinity DataIC50: 2.36E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7459(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4...)
Affinity DataIC50: 2.50E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50033768(2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-(4,5,6-tr...)
Affinity DataIC50: 2.51E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7457(2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromen-4-on...)
Affinity DataIC50: 2.84E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM23410(CHEMBL312163 | 2-(3,4-dihydroxyphenyl)-3,5-dihydro...)
Affinity DataIC50: 2.87E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM26658(2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-...)
Affinity DataIC50: 3.17E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7459(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4...)
Affinity DataIC50: 3.29E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50025974(2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-(4,5,6-tr...)
Affinity DataIC50: 3.85E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM23412(cid_5317284 | 2-(3,4-dihydroxyphenyl)-5,7-dihydrox...)
Affinity DataIC50: 3.91E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50369073(CHEMBL1159644)
Affinity DataIC50: 3.96E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50025974(2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-(4,5,6-tr...)
Affinity DataIC50: 6.00E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM23410(CHEMBL312163 | 2-(3,4-dihydroxyphenyl)-3,5-dihydro...)
Affinity DataIC50: 6.16E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7462(cid_5280863 | CHEMBL150 | 3,5,7-trihydroxy-2-(4-hy...)
Affinity DataIC50: 6.47E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase integrationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50033768(2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-(4,5,6-tr...)
Affinity DataIC50: 6.63E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM50407724(CHEMBL2029094)
Affinity DataIC50: 6.97E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM26658(2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-...)
Affinity DataIC50: 7.65E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM23412(cid_5317284 | 2-(3,4-dihydroxyphenyl)-5,7-dihydrox...)
Affinity DataIC50: 9.43E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrase(Human immunodeficiency virus type 1)
National Cancer Institute-Bethesda

Curated by ChEMBL
LigandPNGBDBM7462(cid_5280863 | CHEMBL150 | 3,5,7-trihydroxy-2-(4-hy...)
Affinity DataIC50: 9.78E+4nMAssay Description:IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavageMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed